BioRestorative Therapies
BRTX
13 hedge funds and large institutions have $541K invested in BioRestorative Therapies in 2023 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 4 closing their positions.
0% more funds holding
Funds holding: 13 → 13 (0)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
0.63% less ownership
Funds ownership: 7.26% → 6.63% (-0.63%)
11% less capital invested
Capital invested by funds: $606K → $541K (-$65.1K)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SG
StoneX Group
New York
|
+$45.6K |
| 2 |
HF
HRT Financial
New York
|
+$23.8K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.61K |
| 4 |
Mariner
Overland Park,
Kansas
|
+$311 |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$177 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Lynwood Capital Management
Toronto,
Ontario, Canada
|
-$35.8K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$32.8K |
| 3 |
FIA
FNY Investment Advisers
New York
|
-$26K |
| 4 |
Wells Fargo
San Francisco,
California
|
-$14.1K |
| 5 |
Two Sigma Advisers
New York
|
-$9.35K |
BRTX Hedge Fund Activity: Q4 2023 in Review
13 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in BioRestorative Therapies (BRTX) for Q4 2023, worth a combined $541K — down 11% from $606K a quarter earlier.
Fund positioning in BRTX was balanced in Q4 2023: 4 funds opened new positions, 4 closed out, 2 added to existing stakes and 3 trimmed.
The largest buyer was StoneX Group, opening a new position worth an estimated $45.6K. The largest seller was Lynwood Capital Management, exiting entirely with an estimated $35.8K sold.
- 13 institutional investors held BioRestorative Therapies (BRTX) as of Q4 2023, unchanged from Q3 2023.
- Funds reported $541K of BioRestorative Therapies stock for Q4 2023, down 11% quarter-over-quarter.
- 4 funds opened new BioRestorative Therapies positions in Q4 2023 and 4 closed out, a net change of 0 holders.
- The largest BioRestorative Therapies buyer in Q4 2023 was StoneX Group, an estimated $45.6K added.
- The largest BioRestorative Therapies seller in Q4 2023 was Lynwood Capital Management, an estimated $35.8K sold.
Based on aggregated 13F filings for Q4 2023.